A recap of the top video interviews from Contemporary OB/GYN's coverage of The Menopause Society 2026 Annual Meeting in San Diego.
|Articles|December 1, 2005
Cerclage: Should we be doing them?
We've been doing cerclage for roughly half a century—but where's the evidence that it prevents preterm birth? The authors make the case for limiting this surgery to select patients, cautioning that for multiple gestations, it might just make things worse.
Advertisement
Diagnosis of cervical insufficiency and indications for cerclage
Advertisement
Related to this article
Susan Reed, MD, MPH, MS, and Calbeth C. Alaribe, DMSc, MPH, PA-C, CPCHE, weigh in on FDA boxed warning removals for menopausal hormone therapy.
The FDA granted accelerated approval to Voceryq to reduce papilloma excision surgeries in adults with recurrent respiratory papillomatosis.
A recap of the top women's health headlines from October 2026, including FDA approval of pritelivir for refractory HSV, ACOG's new menopause guideline, and more.
Chrisandra Shufelt, MD, on using a cardiovascular risk score to guide hormone therapy candidacy at menopause.
The October 30 update from the FDA follows the February 12, 2026 labeling changes to 6 menopausal hormone therapy products in which the agency also removed safety-related boxed warnings.
Neither maternal MOUD dose nor umbilical cord opioid levels were associated with neonatal opioid withdrawal syndrome severity.
Susan Reed, MD, on the need for menopause research funding, a clinical trials network, and studies in understudied groups and perimenopause.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
FDA removes boxed warnings from 3 more menopausal hormone therapy products
2
Reactions to FDA's boxed warning removals for menopausal hormone therapy
3
Choosing Among Hormonal and Nonhormonal VMS Therapies in Menopause
4
FDA grants accelerated approval to DNA immunotherapy for adult recurrent respiratory papillomatosis
5